Update on Management of Type 2 Diabetes for Cardiologists
- Mohammed QureshiEmail Mohammed Qureshi
- Emily Gammoh
- Jawairia Shakil
- Richard Robbins
The management of type 2 diabetes mellitus has evolved over the last several years as new antidiabetic agents continue to arrive and change the goals of diabetes care. In 2008, the U.S. Food and Drug Administration mandated that all new antidiabetic agents must demonstrate cardiovascular (CV) safety, which has led to a series of CV outcome trials. In this article, we review the key findings from these CV outcome trials and their impact on diabetes care guidelines.
- Published on 1 Oct 2018
- Peer Reviewed